Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPX4 | P36969 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | RNF4 | P78317 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17336378 | 0.88 | ALDH1A1 (0.46) | ALDH1A1HTTSMN1; SMN2GPX4MAPT | |
| SCHEMBL17336391 | 0.87 | ALDH1A1 (0.41) | ALDH1A1MAPTCDK8CLK4L3MBTL1 | |
| SCHEMBL23723627 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HTTSMN1; SMN2HDAC6 | |
| SCHEMBL30120738 | 0.82 | ALDH1A1 (0.48) | ALDH1A1HTTSMN1; SMN2HDAC6 | |
| SCHEMBL520092 | 0.79 | LMNA (0.44) | ALDH1A1HTTSMN1; SMN2GPX4MAPT | |
| SCHEMBL9732732 | 0.79 | ALDH1A1 (0.61) | ALDH1A1HTTSMN1; SMN2MAPTKDM4E | |
| SCHEMBL11030800 | 0.77 | HSD17B2 (0.56) | — | |
| SCHEMBL19879909 | 0.76 | ALDH1A1 (0.48) | ALDH1A1HTTSMN1; SMN2MAPTKDM4E | |
| SCHEMBL9836984 | 0.75 | GRM4 (0.42) | ALDH1A1SMN1; SMN2MAPTL3MBTL1KDM4E | |
| SCHEMBL26660394 | 0.75 | ALDH1A1 (0.55) | ALDH1A1HTTSMN1; SMN2MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154634-B1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | UNIV LILLE (FR) | 2021-02-24 | — | — | EP | disclosed |
| US-10323016-B2 | Imidazol- or 1,2,4-triazol-derivatives and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2019-06-18 | — | — | US | disclosed |
| US-20170190687-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | Université de Lille (FR) | 2017-07-06 | — | — | US | disclosed |
| EP-3154634-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189330-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190687-A1 | IMIDAZOL- OR 1,2,4-TRIAZOL-DERIVATIVES AND THEIR USE | CYP3A43, CYP51A1, CYP3A7 | ALDH1A1 436/4885HTT 3734/4885SMN1; SMN2 2642/4885 |
| US-10323016-B2 | Imidazol- or 1,2,4-triazol-derivatives and their use | CYP3A43, CYP51A1, CYP3A7 | ALDH1A1 436/4885HTT 3734/4885SMN1; SMN2 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.